

Health Technology Clinical Committee

Date: November 17, 2023
Time: 9:00 a.m. – 4:00 p.m.
Location: Webinar
Adopted: February 16, 2024

Meeting materials and transcript are available on the [HTA website](#).

HTCC Minutes

Members present: John Bramhall, MD, PhD; Clinton Daniels, DC, MS; Janna Friedly, MD, MPH; Chris Hearne, DNP, MPH; Conor Kleweno, MD; Christoph Lee, MD, MS; Laurie Mischley, ND, MPH, PhD; Sheila Rege, MD; Jonathan Sham, MD; Tony Yen, MD

Clinical expert: Joseph Strunk, MD

HTCC Formal Action

- Welcome and Chair remarks:** Dr. Rege, chair, called the meeting to order; members present constituted a quorum.
- HTA program updates:** Josh Morse, program director, presented HTCC meeting protocols and guidelines, and an overview of the HTA program.
- Previous meeting business:**

July 21, 2023 meeting minutes: Draft minutes reviewed. Motion made and seconded to approve the minutes as written.

Action: Nine committee members approved the July 21, 2023 meeting minutes.

Vote on hyaluronic acid/platelet-rich plasma findings and decision:

Action: Nine committee members voted on draft HA/PRP findings and decision.

Vote on stereotactic body radiation therapy for renal cancer findings and decision:

Action: Six committee members voted on draft SBRT for renal cancer findings and decision.

- Spinal cord stimulation**

Washington State agency utilization and outcomes: Christopher Chen, MD, MBA Medical Director for Medicaid, Health Care Authority, presented the state agency perspective on spinal cord stimulation. Find the full presentation published with the [November 17 meeting materials](#).

Scheduled and open public comments: Chair called for public comments. Comments were provided by:

- Julie Pilitsis, MD – President of North American Neuromodulation Society (NANS)
- Christopher Gharibo, MD – WASIPP/ASIPP (American Society of Interventional Pain Physicians)

Final


- Nilesh Patel, MD – Boston Scientific, Inc. representing manufacturer’s group (Medtronic, Saluda Medical, Nevro Corporation, and Abbott)
- Washington State Physicians SCS Workgroup, represented by:
 - Steven Stanos, DO – Executive Medical Director of Rehabilitation and Performance Medicine Swedish Providence Medical Center; Seattle, WA
 - Brett Stacey, MD – Professor; University of Washington; Seattle, WA
 - Fangfang Xing, MD – Swedish Providence Medical Center; Seattle, WA
- Cindy Steinberg – U.S. Pain Foundation

Vendor report/HTCC questions and answers: Andrea Skelly, PhD, MPH Aggregate Analytics, presented the evidence review for spinal cord stimulation. The full presentation is published with the [November 17 meeting materials](#).

HTCC discussion and action:

Discussion

The committee began their review and discuss of available studies for use of SCS for chronic back pain, complex regional pain syndrome (CRPS), and painful diabetic neuropathy (PDN). Committee deliberation included straw poll voting on the evidence using the Decision Aid. The meeting concluded at this point based on time. The agency medical directors were directed to develop draft coverage criteria for consideration and further discussion by the committee at the next HTCC meeting. Coverage on SCS for each condition was discussed, but a formal vote and draft coverage criteria were not completed by the time the meeting was adjourned. Below is the breakdown of the committee’s evidence votes for safety, efficacy, and cost effectiveness for each condition:



Action

The committee chair directed HTA staff to establish a follow up meeting and for agency medical directors to develop potential draft coverage criteria to continue discussion on SCS and produce draft findings and decision.

5. Meeting adjourned

DRAFT